PRLD biotech catalysts & pipeline

PRELUDE THERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

KAT6A selective degrader — Initial data

2026

The Company expects to advance the program into clinical development in 2026 and generate initial proof-of-concept clinical data, including a potentially differentiated efficacy and safety profile compared to non-selective KAT6A/B inhibitors currently in clinical development.

Source filing

mCALR Precision DACs — IND submission

YE 2026

On Track to Nominate Development Candidate by YE 2026

Source filing

PRT12396 — Initial data

2027

JAK2V617F Mutant Selective JH2 Inhibitors VF+ Myeloproliferative Neoplasms (MPNs) (MF, PV, ET) Phase 1 Early Data 2027

Source filing

PRT12396 — Regulatory decision

1H 2027

JAK2V617F mutant selective inhibitor (PRT12396) IND cleared and Phase 1 study enrollment underway with potential Incyte option exercise decision by 1H 2027

Source filing

PRT13722 — Clinical data readout

Jan 2027–Dec 2028

Key Data Readouts in 2027/2028

Source filing

Explore the free biotech catalyst calendar